Sangamo Biosciences Inc. (SGMO) Stock Research, Analysis & News

Quick Analysis on Sangamo Biosciences Inc. (SGMO) Stock as of October 20, 2017

Previous Closing Price $14.15 is below its 50 day moving average $14.54
Previous Closing Price $14.15 is above 200 day moving average of $9.42
The Stock pays no dividend
The closing price $14.15 is less than 3.18% away from its one year target price of $14.60
Current Short Ratio 8.11 is great than 1
Earning per Share $-0.81 is negative. Sangamo Biosciences Inc. is lossing money.
EBITDA $-57.47M is negative
(See more information about Sangamo Biosciences Inc. (SGMO) Stock below)

Sangamo Biosciences Inc. (SGMO) Stock Profile Summary

Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The companys ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinsons disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC; Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; F. HoffmannLa Roche Ltd; Hoffmann-La Roche Inc.; and Open Monoclonal Technology, Inc. Sangamo BioSciences was founded in 1995 and is based in Richmond, California.

Sangamo Biosciences Inc. (SGMO) Stock Key Statistics Research and Analysis as of October 20, 2017

Stock ExchangeNMS
Market Capitalization$1.17B
Trade Volume (Average Trading Volume)1,325,245 (1,621,830)
Current Year EPS Estimate$-0.82
Next Year EPS Estimate$-0.80
Previous Closing Price$14.15
50 Day Price Moving Average$14.54
200 Day Price Moving Average$9.42
1 yr Target Price$14.60
PEG Ratio0.00
Short Ratio8.11

Sangamo Biosciences Inc. (SGMO) Stock Competitor Research and Analysis

Amgen Inc. (AMGN)Eli Lilly & Co. (LLY)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Sanofi-Aventis (SNY)
Novartis AG (NVS)AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)

Mutual Funds with Sangamo Biosciences Inc. (SGMO) Stock in its top 10 holdings

FundCategorySGMO Holding Percentage
Wasatch Ultra GrowthSmall Growth1.75%

Stock Research on Sangamo Biosciences Inc. (SGMO)

Latest Market News on Sangamo Biosciences Inc. (SGMO)

Click here to find the latest news on Sangamo Biosciences Inc. (SGMO)

Looking for Market Opportunties?

Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Amgen Inc. (AMGN)
Eli Lilly & Co. (LLY)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)